Resonant Clinical Solutions Enhances Global Presence with New Labfish Acquisition
Resonant Clinical Solutions, a prominent name in providing clinical solutions in the life sciences sector, has taken a significant stride forward with its latest acquisition of Labfish, a Germany-based company specializing in rental solutions for lab equipment. This strategic move, announced on September 30, 2026, marks a crucial expansion of Resonant's Equipment and Ancillaries (EA) business, establishing a stronger presence within the European market.
Labfish, with its headquarters located in Hamburg, Germany, is recognized for offering a comprehensive range of laboratory equipment rentals, including essential items such as scales, freezers, and infusion pumps. The company not only provides rental services but also excels in kitting and delivering ancillary supplies necessary for clinical trials, backed by a reputation for top-tier in-house calibration expertise.
The acquisition of Labfish is anticipated to significantly bolster Resonant’s capacity to manage the complexities of modern clinical trial programs on a global scale. As clinical trials evolve, requiring ever-more sophisticated methodologies and equipment, having Labfish on board will enable Resonant to offer enhanced services that align with these demands.
Christophe Berthoux, CEO of Resonant Clinical Solutions, expressed enthusiasm about the acquisition. He stated, "Incorporating Labfish into Resonant's EA business extends our presence in Europe and deepens our calibration and import/export services, further enhancing the world-class clinical trial solutions our customers depend on." This acquisition not only strengthens Resonant's operational capabilities but also underscores the company's commitment to meeting the unique needs of clients engaged in clinical development.
Labfish has been recognized for its operational excellence since its inception in 2014 and holds an ISO 9001 certification, which attests to its commitment to quality management standards. The firm operates one of Europe’s largest in-house calibration facilities specifically designed for clinical trials, further cementing its reliability for clients across the globe. Moreover, Labfish's logistical services, including Importer of Record (IOR) and Exporter of Record (EOR), along with white-glove logistics management capabilities, enable it to seamlessly support more than 70 countries, thanks to partnerships with depots located in various countries including Argentina, Turkey, Israel, and China.
The demand for specialized equipment and adept logistical support within clinical trials is surging, as researchers face increasingly complicated protocols and workflows. The merger of Labfish's robust offerings with Resonant's established services is seen as a natural evolution to meet these growing needs. Martin Forster, founder of Labfish, stated, “Joining Resonant allows our team to further grow the calibration expertise, warehouse network, and import/export and logistics services we've spent years developing, now with the capabilities to support more of the clinical trial journey.” This collaboration is expected to enhance both companies’ abilities to address the rising complexity in clinical trial programs.
Financial terms of the acquisition have not been disclosed, but the implications of this strategic move are profound. With Labfish now under its wing, Resonant Clinical Solutions is poised to further integrate its capabilities and offer a more comprehensive suite of services to its partners, particularly in Europe.
As Resonant continues to facilitate over 2,500 clinical trials and manage around 100 million research assets globally, this acquisition reinforces its proactive approach to supporting clients in the pharmaceutical and biotechnology sectors along with contract research organizations and diagnostic laboratories. The company is dedicated to simplifying the intricacies of the clinical supply chain, allowing scientific innovators to refocus their efforts on groundbreaking research and patient care.
In conclusion, the acquisition of Labfish represents not only a major milestone in Resonant’s business strategy but also a critical enhancement of the services offered to its global customer base, setting the stage for future growth and innovation in the clinical research arena.
Labfish, with its headquarters located in Hamburg, Germany, is recognized for offering a comprehensive range of laboratory equipment rentals, including essential items such as scales, freezers, and infusion pumps. The company not only provides rental services but also excels in kitting and delivering ancillary supplies necessary for clinical trials, backed by a reputation for top-tier in-house calibration expertise.
The acquisition of Labfish is anticipated to significantly bolster Resonant’s capacity to manage the complexities of modern clinical trial programs on a global scale. As clinical trials evolve, requiring ever-more sophisticated methodologies and equipment, having Labfish on board will enable Resonant to offer enhanced services that align with these demands.
Christophe Berthoux, CEO of Resonant Clinical Solutions, expressed enthusiasm about the acquisition. He stated, "Incorporating Labfish into Resonant's EA business extends our presence in Europe and deepens our calibration and import/export services, further enhancing the world-class clinical trial solutions our customers depend on." This acquisition not only strengthens Resonant's operational capabilities but also underscores the company's commitment to meeting the unique needs of clients engaged in clinical development.
Labfish has been recognized for its operational excellence since its inception in 2014 and holds an ISO 9001 certification, which attests to its commitment to quality management standards. The firm operates one of Europe’s largest in-house calibration facilities specifically designed for clinical trials, further cementing its reliability for clients across the globe. Moreover, Labfish's logistical services, including Importer of Record (IOR) and Exporter of Record (EOR), along with white-glove logistics management capabilities, enable it to seamlessly support more than 70 countries, thanks to partnerships with depots located in various countries including Argentina, Turkey, Israel, and China.
The demand for specialized equipment and adept logistical support within clinical trials is surging, as researchers face increasingly complicated protocols and workflows. The merger of Labfish's robust offerings with Resonant's established services is seen as a natural evolution to meet these growing needs. Martin Forster, founder of Labfish, stated, “Joining Resonant allows our team to further grow the calibration expertise, warehouse network, and import/export and logistics services we've spent years developing, now with the capabilities to support more of the clinical trial journey.” This collaboration is expected to enhance both companies’ abilities to address the rising complexity in clinical trial programs.
Financial terms of the acquisition have not been disclosed, but the implications of this strategic move are profound. With Labfish now under its wing, Resonant Clinical Solutions is poised to further integrate its capabilities and offer a more comprehensive suite of services to its partners, particularly in Europe.
As Resonant continues to facilitate over 2,500 clinical trials and manage around 100 million research assets globally, this acquisition reinforces its proactive approach to supporting clients in the pharmaceutical and biotechnology sectors along with contract research organizations and diagnostic laboratories. The company is dedicated to simplifying the intricacies of the clinical supply chain, allowing scientific innovators to refocus their efforts on groundbreaking research and patient care.
In conclusion, the acquisition of Labfish represents not only a major milestone in Resonant’s business strategy but also a critical enhancement of the services offered to its global customer base, setting the stage for future growth and innovation in the clinical research arena.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.